Latest Conference Articles

December 7th 2017, 11:01pm

San Antonio Breast Cancer Symposium

A mix of traditional and customized acupuncture techniques proved effective in reducing pain and stiffness associated with aromatase inhibitor (AI) therapy in women with early-stage breast cancer.

December 7th 2017, 10:25pm

San Antonio Breast Cancer Symposium

The phase III SOLD trial failed to demonstrate that DFS with 9 weeks of adjuvant trastuzumab was noninferior to the standard 12 months when the 2 regimens were combined with chemotherapy in women with early stage HER2-positive breast cancer.

December 7th 2017, 10:03pm

San Antonio Breast Cancer Symposium

Results from a meta-analysis of data collected from 837 premenopausal women undergoing chemotherapy for early-stage breast cancer suggest that gonadotropin-releasing hormone analog may preserve fertility and have a protective ovarian function.

December 7th 2017, 9:55pm

San Antonio Breast Cancer Symposium

Charles Coombes, MD, professor of medical oncology, Imperial College London, discusses surprising results from a recent study examining celecoxib’s impact on breast cancer progression and relapse.

December 7th 2017, 3:50am

San Antonio Breast Cancer Symposium

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the clinical need for immunotherapy regimens for patients with HER2-positive breast cancer.

December 7th 2017, 3:00am

San Antonio Breast Cancer Symposium

Newly released results from the MONALEESA-7 trial showed that adding ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival as a first-line treatment for pre- and perimenopausal women with advanced HR-positive/HER2-negative breast cancer.

December 7th 2017, 2:03am

San Antonio Breast Cancer Symposium

Julie R. Nangia, MD, assistant professor of medicine, Baylor College of Medicine, discusses some logistical factors that oncologists and health care providers should know regarding implementing a scalp cooling system.

December 7th 2017, 1:07am

San Antonio Breast Cancer Symposium

The combination of pembrolizumab and trastuzumab reached an objective response rate of 15.2% in patients with trastuzumab-resistant, PD-L1–positive, HER2-positive breast cancer.

December 6th 2017, 11:57pm

San Antonio Breast Cancer Symposium

Shortening the intervals between chemotherapy cycles or administering the drugs sequentially reduced early-stage breast cancer recurrence and mortality compared with standard dosing techniques.

December 6th 2017, 11:16pm

San Antonio Breast Cancer Symposium

Treatment with sacituzumab govitecan elicited an objective response rate of 34% in patients with heavily pretreated metastatic triple-negative breast cancer.

December 6th 2017, 10:48pm

San Antonio Breast Cancer Symposium

A trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein has shown no significant efficacy, confounding investigators who launched the trial based on opposing results from 2 earlier studies.

December 2nd 2017, 5:00am

SUO Annual Meeting

Treatment with neoadjuvant chemotherapy prior to radical cystectomy significantly improved overall survival compared with cystectomy alone for patients with the basal subtype of muscle-invasive bladder cancer.

December 2nd 2017, 3:47am

SUO Annual Meeting

In a study of neoadjuvant sonidegib in men with high-risk localized prostate cancer undergoing prostatectomy, hedgehog pathway activity was detectable at baseline.

December 2nd 2017, 2:06am

SUO Annual Meeting

Prostate cancer has recently been recognized as a genomically heterogeneous disease with subtypes similar to breast or ovarian cancers.

December 1st 2017, 9:53pm

SUO Annual Meeting

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neoadjuvant immunotherapy trials in renal cell carcinoma (RCC).

December 1st 2017, 9:48pm

SUO Annual Meeting

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing toxicities with checkpoint inhibitors in bladder cancer.

December 1st 2017, 5:00am

SUO Annual Meeting

The established efficacy of single-agent checkpoint inhibition for metastatic urothelial carcinoma along with molecule expression analyses suggests that PD-1/PD-L1 inhibition could hold promise for patients with non-muscle invasive bladder cancer, particularly those unresponsive to Bacillus Calmette-Guérin.

December 1st 2017, 3:07am

SUO Annual Meeting

Both magnetic resonance imaging and prostate cancer antigen 3 tests can predict a positive prostate biopsy and are helpful in identifying high-risk prostate cancer.

December 1st 2017, 1:31am

SUO Annual Meeting

Guru Sonpavde, MD, director of Bladder Cancer at the Dana-Farber Cancer Institute, discusses current clinical trials in penile cancer.

December 1st 2017, 1:22am

SUO Annual Meeting

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the potential combination of IDO inhibitors and PD-1 inhibitors in renal cell carcinoma.